GENFIT Announces Solid H1 2024 Financials and Key Corporate Developments
Sep 20, 2024
Biopharmaceutical Equities
Bronstein, Gewirtz & Grossman, LLC Initiates Investigation into Liquidia Technologies, Inc. for Potential Investor Claims
Sep 3, 2024
Immuron Limited CEO, Steven Lydeamore, to Present at the Emerging Growth Conference
Aug 16, 2024
Nektar Therapeutics NKTR Faces Q2 Earnings Shortfall, Despite Revenue Surge
Aug 10, 2024
NurExone Biologic Inc. Springs Forward with Key Initiatives: Growth Conference Highlights and Website Overhaul
Jul 6, 2024
StockNews.com Begins Analysis of Vanda Pharmaceuticals VNDA
Jul 5, 2024
NurExone Biologic Targets Glaucoma with ExoPTEN in Pre-Clinical Study for Multi-Billion Dollar Market
Jun 30, 2024
Ardelyx Showcases Further Evidence of IBSRELA® Efficacy at 2024 Digestive Disease Week
May 21, 2024
Cognition Therapeutics Concludes $11.5 Million Public Offering
Mar 15, 2024
Halozyme Therapeutics HALO Upgraded to 'Buy' Status Amid Positive Market Outlook
Feb 24, 2024
Liquidia Corporation Announces FDA Update on YUTREPIA™ Inhalation Powder NDA
Jan 25, 2024
Liquidia Corporation Secures $100 Million Boost through New Financial Agreements
Jan 5, 2024
Ardelyx Sets Date for Update on IBSRELA® and IBS-C Sector Expert Discussion
Jan 4, 2024
Ardelyx Announces Upcoming Update on IBSRELA® and Expert Discussion on IBS-C Market
Jan 3, 2024
Assessing the Investment Appeal of Select Dow Stocks in 2024
Dec 30, 2023
Vandria Secures $20.6M in Series A Funding to Propel CNS Clinical Program and Mitochondrial Therapeutics Development
Dec 15, 2023
U.S. Stock Market Sees Broad Gains; Verint Outperforms with Strong Earnings
Dec 7, 2023
Cytokinetics to Present Multiple Studies at the 34th International ALS/MND Symposium
Nov 30, 2023
CytoMed Therapeutics Announces H1 2023 Financial Results and Provides Company Update
Nov 18, 2023